Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Exclusion Criteria

• •1. Prior treatment with \>1week of antiretroviral therapy.
• •2. Patient requires or is anticipated to require any of the prohibited medications noted in the protocol.
• •3. HIV RNA \< 5000 prior to receiving therapy.
• •4. Baseline resistance to any of the study regimen drugs on genotype testing.
• •5. Patients with acute hepatitis due to any cause or clinically significant chronic liver disease.
• •6. Patient with severe renal insufficiency defined as a calculated creatinine clearance at time of screening \<30mL/min, based on the Cockcroft-Gault equation which is as follows (and 0.85X this value for females): Clcr(mL/min) = (l40-age) x weight (in kg)72 x serum creatinine (mg/dL).
• •7. Patient has a condition (including but not limited to alcohol or other substance abuse) which in the opinion of the investigator would interfere with patient compliance or safety.
• •8. A female patient who is pregnant, breast-feeding, or expecting to conceive or donate eggs during the study; or a male patient who is planning to impregnate or provide sperm donation during the study is excluded.
• •9. Inability to obtain signed informed consent from a patient age 18 or older.
• •10. Patient has significant hypersensitivity or other contraindication to any of the components of the study drug.
• •11. Patients who should be treated for hyperlipidemia as per NCEPIII guidelines and patients who are currently receiving lipid-lowering therapy are excluded.